Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Transcon Pth

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT05387070Phase 3Completed

PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Showing all 1 trials

Research Network

Common Treatments

  • Transcon Pth1

Active Sponsors

  • Visen Pharmaceuticals (Shanghai) Co., Ltd.1

Top Investigators

  • Weibo Xia, MD1

    Department of endocrinology, Peking Union Medical College Hospital

Related Conditions

  • Endocrine System Diseases1
  • Parathyroid Diseases1
  • Hypoparathyroidism1

Activity Timeline